NLRP3 data could drive renewed focus on Ventyx candidates, says Jefferies

Jefferies notes that newly published data from a private company suggests that NLRP3 inhibition may reduce body weight in mice and could be tested in obesity, either as a monotherapy or in combination with GLP-1 drugs. Ventyx Biosciences, which “trades well below cash,” has two NRLP3 drugs in development that it has been testing for inflammatory and central nervous system, or CNS, diseases. Given the growing interest in novel obesity targets, preclinical and upcoming clinical data on NRLP3 “could drive a renewed focus,” says the analyst, who has a Buy rating and $5 price target on Ventyx shares, which are up $2.03, or 68%, to $5.02 in early afternoon trading.